(Reuters) – Synairgen Plc (SYNG.L) stated on Monday its drug helped minimize the risk of extreme cases in hospitalised patients with COVID-19, according to information from a trial of more than 100 individuals in the United Kingdom, sending its shares escalating. Patients who got the drug, SNG001, were more than twice as likely to recover from COVID-19 as those on placebo, the business stated. The company said that no deaths were reported in clients treated with SNG001, while 3 individuals died after being randomised to placebo.
- Enzymatica shares jump as company says mouth spray can deactivate COVID-19 – MarketWatch
- Some ICUs in Florida have run out of beds – CBS News